Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

LC/MS Solvents

By Drug Discovery Trends Editor | April 8, 2010

mbakerMallinckrodt Baker’s J.T.Baker ULTRA Liquid Chromatography/Mass Spectrometry (LC/MS) solvents are designed for the most demanding ultra-high pressure liquid chromatography (UHPLC) and mass spectrometry research and analytical testing applications, such as proteomics, drug discovery, pharmacokinetics and clinical research.

Through a combination of process and packaging enhancements, the ULTRA LC/MS solvents are intended to deliver enhanced instrument performance and extend the useful life of UHPLC columns by controlling trace metal impurities, organic impurities and particle levels. The solvents are filtered through 0.1 micrometer filters which provide extremely low particle counts, and are packaged in 1 L borosilicate bottles that minimize leaching of trace metal impurities. Enhanced suitability testing is performed to ensure that key organic impurities, such as polyethylene glycol (PEG) and phthalates, are controlled throughout the manufacturing and packaging processes.

“As the use of advanced instrumentation in the most demanding research and analytical testing applications grows, the need for ultra high-purity solvents has increased. Low-level chemical impurities can cause metal adduct formation which can lead to erroneous peaks,” said Russell Thorpe, global marketing director, Mallinckrodt Baker. “Our J.T.Baker ULTRA LC/MS solvents have been designed to meet strict quality requirements, which optimize UHPLC instrument performance and reduce the need for costly rework.”

Mallinckrodt Baker 

This product was featured in Drug Discovery & Development magazine: Vol. 13, No. 3, April 2010, p. 8.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE